Cheryl Gault is Director at Rapport Therapeutics, Inc. (RAPP). They have made 5 open-market trades across 1 company since 2026, most recently 2026-10-30.
CIK 2012593
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $21.8M since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RAPP | 2,159,694 | $56.0M |
Shares reported on the most recent Form 4, priced at the 2026-11-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RAPP | BUY | 2026-10-28 | 2026-10-30 | $21.00 | $20.4M | — | — | — |
| RAPP | BUY | 2026-10-23 | 2026-10-23 | $27.35 | $98K | -1.1% | — | — |
| RAPP | BUY | 2026-10-22 | 2026-10-22 | $27.28 | $974K | -7.1% | — | — |
| RAPP | BUY | 2026-10-22 | 2026-10-22 | $27.08 | $100K | -7.1% | — | — |
| RAPP | BUY | 2026-10-22 | 2026-10-22 | $26.45 | $249K | -7.1% | — | — |
| RAPP | SELL · 10b5-1 | 2026-10-21 | 2026-10-23 | $29.16 | $64K | -1.1% | — | — |
| RAPP | SELL · 10b5-1 | 2026-10-06 | 2026-10-08 | $31.68 | $143K | -1.8% | — | — |
| RAPP | SELL · 10b5-1 | 2026-09-30 | 2026-10-01 | $33.19 | $332K | -11.1% | -23.0% | — |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.